Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
07 November 2023 - 10:12PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
November 6, 2023
________________
NOVO NORDISK A/S
(Exact name of
Registrant as specified in its charter)
Novo Allé
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under cover
of Form 20-F or Form 40-F
Form 20-F [X] |
Form 40-F [ ] |
Trading in Novo Nordisk shares by board members, executives
and associated persons
Bagsværd, Denmark, 6 November 2023 — This company announcement discloses
the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons
in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
The company’s board members, executives and their associated persons have given Novo Nordisk
power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their
associated persons.
Please find below a statement of such trading in shares issued by Novo Nordisk.
1 |
Details of the person discharging managerial responsibilities/person closely associated |
a) |
Name of the Board member/Executive/Associated Person |
Novo Holdings A/S, associated to Kasim Kutay |
2 |
Reason for the notification |
a) |
Position/status |
Member of the Board of Directors |
b) |
Initial notification/Amendment |
Initial notification |
3 |
Details of the issuer |
a) |
Name |
Novo Nordisk A/S |
b) |
LEI |
549300DAQ1CVT6CXN342 |
4 |
Details of the transaction(s) |
Novo Nordisk A/S
Investor Relations |
Novo Allé
2880 Bagsværd
Denmark |
Telephone:
+45 4444 8888 |
Internet:
www.novonordisk.com
CVR no:
24 25 67 90 |
|
|
Company announcement No 73 / 2023 |
a) |
Description of the financial
instrument, type of instrument, |
Shares |
|
Identification code |
Novo Nordisk B DK0060534915 |
b) |
Nature of the transaction |
Sale of shares |
c)
|
Price(s) and volume(s)
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
DKK 696.76 |
7,012,500 shares |
|
|
|
|
|
|
|
|
|
d) |
Aggregated information
|
7,012,500 shares
DKK 696.76 |
e) |
Date of the transaction |
2023-11-06 |
f) |
Place of the transaction |
Outside a trading venue |
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in
Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering
scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs
about 61,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen
(Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.
Contacts for further information
Media: |
|
Ambre James-Brown
+45 3079 9289
abmo@novonordisk.com |
Elizabeth DeLuca (US)
+1 609 580 9868
edel@novonordisk.com |
|
|
Investors: |
|
Daniel Muusmann Bohsen
+45 3075 2175
dabo@novonordisk.com |
Jacob Martin Wiborg Rode
+45 3075 5956
jrde@novonordisk.com |
Novo Nordisk A/S
Investor Relations |
Novo Allé
2880 Bagsværd
Denmark |
Telephone:
+45 4444 8888 |
Internet:
www.novonordisk.com
CVR no:
24 25 67 90 |
|
|
Company announcement No 73 / 2023 |
David Heiberg Landsted
+45 3077 6915
dhel@novonordisk.com |
Mark Joseph Root (US)
+1 848 213 3219
mjhr@novonordisk.com |
|
|
Sina Meyer +45 3079 6656
azey@novonordisk.com |
Frederik Taylor Pitter +45 3075 8259
fptr@novonordisk.com |
Novo Nordisk A/S
Investor Relations |
Novo Allé
2880 Bagsværd
Denmark |
Telephone:
+45 4444 8888 |
Internet:
www.novonordisk.com
CVR no:
24 25 67 90 |
|
|
Company announcement No 73 / 2023 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly
caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
Date: November 6, 2023 |
NOVO NORDISK A/S
Lars Fruergaard Jørgensen
Chief Executive Officer |
Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From Apr 2024 to May 2024
Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From May 2023 to May 2024